Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD1 | P21728 | 3/20 | 0.36 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29605226 | 1.00 | FYN (0.40) | FYNADRA1ADRD2DRD1UGT2B17 | |
| Hydrochloric Acid SCHEMBL10446675 | 0.98 | FYN (0.39) | FYNADRA1ADRD2DRD1UGT2B17 | |
| SCHEMBL24095324 | 0.80 | FYN (0.38) | FYNADRA1ADRD2AADATCA1 | |
| SCHEMBL19393517 | 0.80 | FYN (0.38) | FYNADRA1AAADATCA1CA2 | |
| SCHEMBL25961964 | 0.79 | DRD2 (0.36) | DRD2DRD1UGT2B17ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL25284020 | 0.79 | FYN (0.36) | FYNADRA1AAADATCA1CA2 | |
| SCHEMBL23330750 | 0.77 | FYN (0.35) | FYNADRA1A | |
| SCHEMBL415656 | 0.77 | DRD2 (0.37) | DRD2DRD1UGT2B17ALDH1A1MAPT | |
| SCHEMBL29511500 | 0.77 | DRD2 (0.37) | DRD2DRD1UGT2B17ALDH1A1MAPT | |
| SCHEMBL18466748 | 0.75 | DRD2 (0.36) | DRD2DRD1UGT2B17ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112500301-B | Regulator for longitudinal behavior | 以西结·戈兰 | 2024-02-13 | — | — | CN | claimed |
| US-20250288541-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2025-09-18 | — | — | US | disclosed |
| US-12357590-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-12350242-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2025-07-08 | — | — | US | disclosed |
| US-12064402-B2 | Binge behavior regulators | Clearmind Medicine Inc. (CA) | 2024-08-20 | — | — | US | disclosed |
| WO-2024062395-A1 | USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME | Clearmind Medicine Inc. (IL) | 2024-03-28 | — | — | WO | disclosed |
| CN-112500301-B | Regulator for longitudinal behavior | 以西结·戈兰 | 2024-02-13 | — | — | CN | disclosed |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Clearmind Medicine Inc. (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11528924-B2 | Alcoholic beverage substitutes | Clearmind Medicine, Inc. (CA) | 2022-12-20 | — | — | US | disclosed |
| CN-114903134-A | Alcoholic beverage substitute | 以西结·戈兰 | 2022-08-16 | — | — | CN | disclosed |
| US-20170360067-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | CLEARMIND LABS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| CN-107406369-A | Relaxant behavior modulators | 以西结·戈兰 | 2017-11-28 | — | — | CN | disclosed |
| CN-107406370-A | Alcoholic beverage substitute | 以西结·戈兰 | 2017-11-28 | — | — | CN | disclosed |
| EP-3230255-A1 | BINGE BEHAVIOR REGULATORS | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230256-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092546-A1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092547-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| US-5708018-A | 2-aminoindans as selective dopamine D3 ligands | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0712387-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004713-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | THE UPJOHN COMPANY (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288541-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | FYN 4855/4885ADRA1A 1345/4885DRD2 62/4885 |
| US-20230092839-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | ADH1A, ADH5, ADH1C | FYN 3559/4885ADRA1A 1477/4885DRD2 456/4885 |
| US-12350242-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | FYN 4855/4885ADRA1A 1345/4885DRD2 62/4885 |
| US-12064402-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | FYN 4855/4885ADRA1A 1345/4885DRD2 62/4885 |
| US-11528924-B2 | Alcoholic beverage substitutes | ADH1A, ADH5, ADH1C | FYN 3559/4885ADRA1A 1477/4885DRD2 456/4885 |
| US-12357590-B2 | Binge behavior regulators | GABRB3, GABRB2, GABRB1 | FYN 4855/4885ADRA1A 1345/4885DRD2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.